In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

MGI Pharma to buy Guilford Pharmaceuticals for $174mm

Executive Summary

MGI Pharma has agreed to acquire all of Guilford Pharmaceuticals' 46.5mm outstanding shares for stock and cash totaling about $174mm. It will pay $3.75 per share (a 62% premium), comprising a fractional share of MGI stock worth $2.625--the exact fraction to depend on MGI's trading price just before the deal closes--plus $1.13 in cash.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Intra-Biotech Deal
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies